APOE and metabolic syndrome: This result seem to suggest that E4 allele capability to determine higher prevalence of CVD would be entailed by MetS presence, corroborating Apolipoprotein E modulation of atherogenic plasma Apo-B containing lipoproteins seen in this disorder.